Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality.


Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
11 2019
Historique:
received: 17 07 2019
revised: 05 09 2019
accepted: 07 09 2019
pubmed: 14 9 2019
medline: 21 10 2020
entrez: 14 9 2019
Statut: ppublish

Résumé

The aim of our study was to investigate outcomes of patients with ATTR (amyloidosis and transthyretin) CA (cardiac amyloidosis) and implantable devices with respect to left ventricular ejection fraction (LVEF), mitral regurgitation (MR), New York Heart Association (NYHA) functional class, and mortality. This was a retrospective observational cohort study of 78 patients with ATTR CA and implantable devices. During a mean follow-up of 42 months we investigated the impact of right ventricular (RV) pacing burden and biventricular (BiV) pacing on LVEF, MR severity, NYHA functional class, and mortality. Worsening MR occurred in 11% of patients with a RV pacing % <40% compared to 62% of those with a RV pacing burden >40% (P = .002). Similarly, worsening LVEF occurred in 26% of patients who were RV paced <40% and 89% of those who were RV paced >40% of the time (P < .0001) and worsening in NYHA functional class occurred in 22% and 89%, respectively (P < .0001). Improvement in LVEF, NYHA functional class, and MR severity occurred in 78%, 67%, and 67%, respectively, in those with BiV devices. Death occurred in 67% of patients in the cardiac resynchronization therapy group compared to 68% of those with a RV pacing burden <40% and 92% of those with a RV pacing burden >40%. A higher RV pacing burden is associated with deleterious remodeling and congestive heart failure in patients with ATTR CA, whereas BiV pacing is associated with improvements in LVEF, NYHA class, and degree of MR. BiV pacing should be considered in patients with ATTR CA and an indication for pacing. However, further larger prospective studies will need to be performed.

Sections du résumé

BACKGROUND
The aim of our study was to investigate outcomes of patients with ATTR (amyloidosis and transthyretin) CA (cardiac amyloidosis) and implantable devices with respect to left ventricular ejection fraction (LVEF), mitral regurgitation (MR), New York Heart Association (NYHA) functional class, and mortality.
METHODS
This was a retrospective observational cohort study of 78 patients with ATTR CA and implantable devices. During a mean follow-up of 42 months we investigated the impact of right ventricular (RV) pacing burden and biventricular (BiV) pacing on LVEF, MR severity, NYHA functional class, and mortality.
RESULTS
Worsening MR occurred in 11% of patients with a RV pacing % <40% compared to 62% of those with a RV pacing burden >40% (P = .002). Similarly, worsening LVEF occurred in 26% of patients who were RV paced <40% and 89% of those who were RV paced >40% of the time (P < .0001) and worsening in NYHA functional class occurred in 22% and 89%, respectively (P < .0001). Improvement in LVEF, NYHA functional class, and MR severity occurred in 78%, 67%, and 67%, respectively, in those with BiV devices. Death occurred in 67% of patients in the cardiac resynchronization therapy group compared to 68% of those with a RV pacing burden <40% and 92% of those with a RV pacing burden >40%.
CONCLUSION
A higher RV pacing burden is associated with deleterious remodeling and congestive heart failure in patients with ATTR CA, whereas BiV pacing is associated with improvements in LVEF, NYHA class, and degree of MR. BiV pacing should be considered in patients with ATTR CA and an indication for pacing. However, further larger prospective studies will need to be performed.

Identifiants

pubmed: 31515942
doi: 10.1111/jce.14180
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2427-2432

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Eoin Donnellan (E)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Oussama M Wazni (OM)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Walid I Saliba (WI)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Bryan Baranowski (B)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Mazen Hanna (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Michael Martyn (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Divyang Patel (D)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Kevin Trulock (K)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Venu Menon (V)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Ayman Hussein (A)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Philip Aagaard (P)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Wael Jaber (W)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Mohamed Kanj (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH